Search for companies, drugs, and catalysts
Phase 2
Development Phase
1
Upcoming Catalysts
0
Historical Events
Regulatory Approvals
VIR-2218 Phase 2 Results Expected
VIR-2218 • Hepatitis B, Chronic
Target Indication
Hepatitis B, Chronic
Clinical Trial
Last updated: 12/4/2025
VIR
Vir Biotechnology, Inc.